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Background & Aims:We aimed to elucidate whether hepatic
insulin resistance may contribute to hepatocyte apoptosis and
ﬁbrogenesis in nonalcoholic fatty liver disease (NAFLD) and in
chronic hepatitis C virus (HCV) infection.
Methods: Twenty-seven nonalcoholic steatosis (NAST), 24 nonal-
coholic steatohepatitis (NASH), 71 HCV, and 29 patients with his-
tological normal liver (NL) were studied. Real-time PCR, the
TUNEL assay, and Western blots were used to assess insulin-
signaling molecules, hepatocyte apoptosis, antiapoptotic media-
tors, active caspase 3, and type I collagen in liver biopsies. HCV
core-transfected human hepatocytes were used as an in vitro
model.
Results: In NAFLD patients, hepatic levels of insulin receptor
substrate (IRS) 1, IRS2 2, the p85a subunit of phosphatidylinositol
3-kinase (p85a), phosphorylated protein kinase B (pAkt), phos-
phorylated forkhead box-containing protein O subfamily-1
(FoxO), and phosphorylated 50 adenosine monophosphate-acti-
vated protein kinase (pAMPK) as well as the antiapoptotic medi-
ators B-cell lymphoma 2 protein (Bcl-2) and myeloid cell
leukemia protein-1 (Mcl-1) were signiﬁcantly lower in NASH
than in NAST and NL. Furthermore, hepatocyte apoptosis and
increased active caspase 3 were only present in NASH. In HCV
patients, hepatic insulin signaling was markedly impaired,
regardless of viral genotype and the presence of steatosis paral-
leled with enhanced apoptosis. In cultured human hepatocytes,
HCV core protein decreased pAkt and increased phosphorylation
of c-Jun N-terminal kinase (JNK). This effect was more pro-
nounced in lipid-loaded hepatocytes.
Conclusions:Hepatic insulin signaling is impaired in NASH and
HCV patients, and downregulation of insulin-sensitive targets is
associated with increased apoptosis and ﬁbrogenesis in both con-
ditions. JNK might be a target for HCV-induced insulin resistance.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Introduction
Nonalcoholic fatty liver disease (NAFLD) and chronic hepatitis C
virus (HCV) infection are the commonest causes of chronic liver
disease in Western countries [1,2]. A number of epidemiologic
and clinical studies have shown a close association between fatty
liver and insulin resistance (IR) [3,4]. The physiopathological con-
sequences of IR depend on whether the impairment of insulin
receptor signaling is in peripheral tissues or in the liver. In
peripheral tissues, IR maintains the activity of the hormone-
sensitive lipase, increasing free fatty acids in the plasma and
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reaching the liver [5]. On the other hand, the main consequence
of hepatic IR, due to impaired insulin receptor substrate (IRS)
phosphorylation [6], is an increased hepatic glucose production
resulting from a failure to suppress gluconeogenesis. Moreover,
de novo lipid synthesis remains stimulated despite impairment
of hepatic insulin signaling [7], leading to fat accumulation
within the liver.
In NAFLD patients, some authors found that IR does not inﬂu-
ence the progression rate of ﬁbrosis [8], whereas others reported
that IR is signiﬁcantly associated with severe ﬁbrosis [9]. In HCV
patients, IR develops early in the course of the disease and pre-
cedes steatosis [10]. Moreover, it has been reported that IR is
independently associated with histological severity and nega-
tively affects treatment response [11,12]. Supporting the hypoth-
esis that IR could be a pathogenic factor shared by NAFLD and
chronic HCV infection, the enhancement of insulin sensitivity
improves some clinical and histological features in both liver dis-
eases [13,14].
While there is growing clinical evidence that IR may con-
tribute to disease progression in NAFLD and chronic HCV infec-
tion, the extent of impairment of hepatic insulin signaling, the
pathways involved, and its impact on liver injury and ﬁbrosis
in both conditions remain to be deﬁned. Therefore, the aims
of the present study were ﬁrst to determine the extent of
impairment of hepatic insulin signaling and the pathways
involved and second, to assess its relationship with liver dam-
age parameters, such as apoptosis and ﬁbrosis in NAFLD and
HCV patients. We have also evaluated the effects of lipid accu-
mulation and the HCV per se on insulin signaling in cultured
human hepatocytes.
Table 1. Demographic, metabolic, biochemical, and histopathological characteristics of patients with normal liver and nonalcoholic fatty liver disease.
Characteristics 
Age (years) 
Women/Men 
Body mass index (kg/m2) 
Glucose (mg/dl)  
Insulin (µU/L)  
HOMA-IR 
Triglycerides (mg/dl) 
HDL-cholesterol (mg/dl) 
Metabolic syndrome (%) 
ALT (IU/L) 
AST (IU/L) 
γ -GT (IU/L) 
Steatosis (%) 
   Grade 0 
   Grade 1 
Grade 2 
Grade 3 
Fibrosis (%) 
   Stage 0 
Stage 1
Stage 2
Stage 3
   Stage 4 
Ballooning and lobular inflammation (%) 
   Grade 0 
Grade 1
NAST 
(n = 27) 
47.1 ± 11.2 
16 (59.3%)/ 11 (40.7%)
26.1 ± 2.5 
94.3 ± 9.5 
10.9 ± 7.8 
1.67 ± 1.1* 
147.3 ± 53.6* 
46.8 ± 12.7 
5 (18.5%)* 
26.3 ± 12.1* 
21.3 ± 10.4 
78.4 ± 53.7* 
14 (51.9%) 
10 (37.0%) 
 3 (11.1%) 
27 (100%) 
27 (100%) 
Grade 2
NL 
(n = 29) 
46.9 ± 10.6 
17(58.6%)/ 12 (41.4%)
25.8 ± 2.7 
89.6 ± 6.5 
8.7 ± 4.6 
0.96 ± 0.5 
99.4 ± 26.2 
49.3 ± 9.7 
0 (0%) 
16.7 ± 5.9 
15.3 ± 6.6 
27.1 ± 14.6 
29 (100%) 
29 (100%) 
29 (100%) 
Grade 3
   Grade 4 
NASH 
(n = 24) 
47.5 ± 9.7 
14 (58.3%)/ 10 (41.7%)
26.4 ± 2.4 
92.1 ± 8.3 
11.2 ± 8.1 
1.98 ± 1.6* 
171.5 ± 59.6* 
45.3 ± 10.2 
7 (29.2%)* 
61.8 ± 31.5*# 
37.3 ± 15.6* 
93.5 ±  62.8* 
12 (50.0%) 
 8 (33.3%) 
 4 (16.7%)
6 (25.0%)
9 (37.5%) 
6 (25.0%)
3 (12.5%) 
13 (54.2%)
10 (41.7%) 
1 (4.1%) 
Data are shown as mean ± standard deviation or as number of cases (%). NL, normal liver; NAST, nonalcoholic steatosis; NASH, nonalcoholic steatohepatitis; HOMA-IR,
homeostatic model assessment-insulin resistant; HDL, high-density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; and c-GT, gamma-
glutamyltransferase.*p <0.05 with respect to NL group. #p <0.05 with respect to NAST group.
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Patients and methods
Patients
This study comprised 122 nondiabetic patients with a clinical diagnosis of either
NAFLD or chronic HCV infection who underwent a liver biopsy with diagnostic
purposes. We further studied 29 subjects with histologically normal liver (NL).
Liver tissue studies
Histopathology assessment
Parafﬁn-embedded liver biopsy sections were evaluated by a single hepatopathol-
ogist blinded to the clinicaldata.Overall, steatosiswasassessedasoutlinedbyBrunt
et al. [15], and theKleiner’s histological scoring [16]was used to evaluate thedegree
ofhepatocellular ballooningand lobular inﬂammation aswell as the stageofﬁbrosis
in NAFLD. Patients with NAFLD were classiﬁed into two groups: those with
simple steatosis (NAST) and those with deﬁnite steatohepatitis (NASH). In the
HCV group, the grade of necroinﬂammation and the stage of ﬁbrosis were scored
as proposed by Scheuer [17]. HCV patients were categorized into three groups,
depending on whether they were infected with genotype 1(HCV G1) or genotype
3 (HCV G3) and on the presence of steatosis in HCV G1 patients (HCV G1 + NAST).
TUNEL assay
For the detection of apoptosis, the TUNEL commercial kit for cell death detection
(Roche Biochemicals, Mannheim, Germany) was used following the instructions
of the manufacturer. DAPI was used for DNA staining.
RNA isolation and quantitative real-time PCR analysis
Total RNA of liver biopsy samples from all patients was extracted by using TRIzol
reagent (Invitrogen, Carlsbad, CA). Total RNA (1 lg) was reverse transcribed
using a SuperScript™ III First-Strand Synthesis System for qPCR following the
Table 2. Demographic, metabolic, biochemical, viral, and histopathological characteristics of patients with chronic hepatitis C virus infection.
Characteristics
Age (years) 
Women/Men 
Body mass index (kg/m2) 
Glucose (mg/dl) 
Insulin (µU/L)  
HOMA-IR 
Triglycerides (mg/dl) 
HDL-cholesterol (mg/dl) 
Metabolic syndrome (%) 
ALT (IU/L) 
AST (IU/L) 
γ -GT (IU/L) 
HCV viral load (%) 
 8.5 x 105 IU/ml  
   > 8.5 x 105 IU/ml  
Steatosis (%) 
Grade 0
Grade 1
Grade 2
   Grade 3 
Fibrosis (%) 
   Stage 0 
   Stage 1 
   Stage 2 
   Stage 3 
   Stage 4 
Necroinflammation (%)
Grade 0
   Grade 1 
   Grade 2 
Grade 3 
HCV G1 
(n = 24) 
47.0 ± 11.1 
14 (58.3%) / 10 (41.7%)
25.7 ± 2.6 
86.3 ± 10.1 
10.5 ± 5.8 
1.97 ± 1.2 
96.4 ± 41.3 
51.1 ± 16.3 
0 (0%) 
105.4 ± 65.1 
59.7 ± 30.5 
39.7 ± 18.4 
7 (29.2%) 
17 (70.8%) 
24 (100%)
9 (37.5%) 
4 (16.7%) 
4 (16.7%) 
5 (20.8%) 
2 (8.3%) 
7 (29.2%) 
11 (45.8%) 
6 (25.0%) 
HCV G1+NAST 
(n = 28) 
46.7 ± 10.6 
17 (60.7%) / 11 (39.3%)
26.3 ± 2.5 
88.1 ± 10.3 
10.7 ± 6.6 
2.01 ± 1.6 
98.1 ± 43.5 
50.4 ± 15.2 
0 (0%) 
98.4 ± 57.2 
54.1 ± 34.7 
67.3 ± 38.2* 
9 (32.2%) 
19 (67.8%) 
19 (67.9%) 
6 (21.4%) 
3 (10.7%) 
12 (42.8%) 
5 (17.9%) 
5 (17.9%) 
4 (14.3%) 
2 (7.1%) 
8 (28.6%) 
12 (42.8%) 
8 (28.6%) 
HCV G3 
(n = 19) 
47.2 ± 10.2 
11 (57.9%) / 8 (42.1%) 
25.9 ± 2.7 
87.6 ± 9.7 
10.2 ± 5.3 
1.64 ± 0.9 
95.6 ± 40.2 
50.7 ± 13.8 
0 (0%) 
112.7 ± 63.5 
51.9 ± 28.9 
64.1 ± 33.5* 
6 (31.6%) 
13 (68.4%) 
12 (63.1%) 
4 (21.1%) 
3 (15.8%) 
7 (36.8%) 
3 (15.8%) 
4 (21.1%)
4 (21.1%)
1 (5.2%) 
4 (21.1%) 
10 (52.6%) 
5 (26.3%) 
   Grade 4 
Data are shown as mean ± standard deviation or as number of cases (%). HCV G1, hepatitis C virus genotype 1; HCV G1+NAST, hepatitis C virus genotype 1 with nonalcoholic
steatosis; HCV G3, hepatitis C virus genotype 3; HOMA-IR, homeostatic model assessment-insulin resistant; HDL, high-density lipoprotein; ALT, alanine aminotransferase;
AST, aspartate aminotransferase; and c-GT, gamma-glutamyltransferase. *p <0.05 with respect to HCV G1 group.
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manufacturer’s instructions (Invitrogen). qPCR was performed with an ABI 7900
sequence detector using the SyBr Green method and d(N)6 random hexamer with
primers.
Speciﬁc primers were purchased from Invitrogen. PCR thermocycling param-
eters were 95 C for 10 min, 40 cycles of 95 C for 15 s, and 60 C for 1 min. Each
sample was run in triplicate and was normalized to 18S RNA. Fold changes were
determined using the DDCt method.
Protein extraction and Western blot analysis
Liver biopsy samples from all patients were homogenized in a medium
containing: 10 mM Tris–HCl, pH 7.5; 1 mM MgCl2, 1 mM EGTA, 10% glycerol,
0.5% 3-(3-cholamidopropyl) dimethylammonio-1-propanesulfonate (CHAPS),
1 mM-mercaptoethanol, and 0.1 mM PMSF. Extracts were vortexed for 30 min
at 4 C and after centrifuging 20 min at 13,000g the supernatants were stored
at 80 C. Protein levels in whole cell lysates were determined with Bradford
reagent (BioRadLaboratories, Richmond, CA). Western blot experiments were
performed.
Cell culture studies
Plasmid constructs
The expression vector pEF1a has been described previously as pcDEF [18]. The
expression vector pEF-core was obtained by subcloning into pEF1a a PCR frag-
ment encoding full-length core protein from HCV genotype 1b.
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Fig. 1. Hepatic mRNA expression of IRS1, IRS2, and p85a is decreased in NASH and HCV patients. Levels of IRS1, IRS2, and p85a transcripts in liver samples from NL
(n = 29), NAST (n = 27), NASH (n = 24), HCV G1 (n = 24), HCV G1 + NAST (n = 28), and HCV G3 (n = 19). (A) Values represent fold relative to NL (1.0). (B) Values represent fold
relative to HCV G3 (1.0). (C) Representative Western blotting showing the expression of these proteins. (D) Bar graph shows the mean ± SD of hepatic protein amount in the
same study groups. Data are the ratio of a target band density to b-actin band density and are presented as percentage relative to NL (100%). *p <0.05, **p <0.001 vs. NL. NL,
normal liver; NAST, nonalcoholic steatosis; NASH, nonalcoholic steatohepatitis; HCV G1, hepatitis C virus genotype 1; HCV G1+NAST, hepatitis C virus genotype 1 with
nonalcoholic steatosis; HCV G3, hepatitis C virus genotype 3; INSR, insulin receptor.
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Stable transfectants
Chang liver (CHL) cells (CCL13; American Type Culture Collection, Manassas, VA)
were grown at 37 C with 5% CO2 in DMEM supplemented with 10% (v/v) fetal calf
serum (BioWhittaker, Walkersville, MD). Polyclonal transfectants CHL-core 1b
derived from CHL cells were generated by stably transfecting these cells with
the plasmid pEF1a-cDNA EF core 1b as previously described [19]. We also gener-
ated transfectants CHL-cat by stable transfection of CHL cells with a vector driv-
ing the expression of the bacterial chloramphenicol acetyltransferase (cat) gene,
which were used as controls. Where indicated, CHL cells were stimulated with
10 nM insulin (Sigma–Aldrich) for 10 min. Moreover, CHL cells were incubated
with culture medium supplemented with 100 lM stearic acid dissolved in isopro-
panol or with vehicle alone for 24 h either to induce lipid accumulation or to use
as controls.
Statistical analysis
Categorical variables are presented as frequency and percentage. Continuous
variables are shown as mean ± standard deviation. The baseline characteristics
of the patients studied were compared by the Pearson v2 test for categorical vari-
ables and the unpaired t test or Mann–Whitney U test for continuous variables.
Data from qPCR and Western blotting were compared by using the Kruskal–Wal-
lis ANOVA test. The Spearman’s r-test was used to evaluate correlations. All sta-
tistical analyses were performed using SPSS version 15.0 (SPSS, Cary, NC)
software with 2-sided tests, with a p value of <0.05 considered as statistically
signiﬁcant.
Results
Patient characteristics
Characteristics of NAFLD and HCV patients studied are detailed in
Tables 1 and 2, respectively. To highlight, all patient groups were
well matched in terms of age, sex distribution, and BMI. In the
NAFLD cohort, NAST patients had signiﬁcantly higher mean
HOMA-IR score (p = 0.009), triglycerides (p = 0.031), the rate of
metabolic syndrome (p = 0.017), ALT (p = 0.007), and c-GT
(p <0.001) than subjects with NL. In NASH patients, the mean
HOMA-IR score, triglycerides, the frequency of metabolic syn-
drome; ALT, AST, and c-GT were signiﬁcantly higher than in NL
individuals (p = 0.005, p = 0.027, p <0.001, p <0.001, p = 0.002
and p <0.001, respectively). Moreover, NASH patients had signif-
icantly higher serum ALT levels than NAST patients (p = 0.013).
Regarding HCV patients, the lower serum levels of c-GT in
HCV G1 patients than in HCV G1 + NAST and in HCV G3 cohorts
(p = 0.034 and p = 0.038) were the only signiﬁcant differences
among HCV groups.
Hepatic insulin signaling is impaired in NASH and HCV patients
Hepatic mRNA levels of IRS1, IRS2, and p85a were lower in
patients with NASH (0.47, 0.41, and 0.59-fold, respectively) than
in NL subjects, remaining unchanged in NAST patients (Fig. 1A,
left). Furthermore, the expression of these transcripts were sig-
niﬁcantly decreased in the liver of patients with HCV G1 (0.96,
0.94, and 0.98-fold, respectively), HCV G1 + NAST (0.93, 0.92,
and 0.96-fold, respectively), and HCV G3 (0.93, 0.91, and 0.96-
fold, respectively) with respect to NL (Fig. 1A, left). When the
HCV G3 group was used as control and comparing with HCV G1
and HCV G1 + NAST, no signiﬁcant differences in the hepatic
mRNA levels of IRS1, IRS2, and p85a were found (Fig. 1A, right).
Likewise, a decrease in the hepatic protein amount of IRS1,
IRS2, and p85a was found in NASH (60%, 38%, and 54%, respec-
tively), HCV G1 (79%, 39%, and 55%, respectively), HCV G1 + NAST
(62%, 66%, and 70%, respectively), and HCV G3 (85%, 66%, and 49%,
respectively) as compared with NL and NAST patients (Fig. 1B and
C). Akt and AMPKa are relevant downstream insulin mediators
[20]. As shown in Fig. 2, pAkt/Akt and pAMPKa/AMPKa ratios
were decreased in NASH (28% and 56%, respectively), HCV G1
(52% and 62%, respectively), HCV G1 + NAST (59% and 50%,
respectively), and HCV G3 (78% and 59%, respectively) but not
in NAST patients compared with NL. Next, we analyzed the
expression and phosphorylation of the insulin-induced transcrip-
tion factor FoxO1 [21]. The hepatic content of pSer256-FoxO1,
when compared with NAST and NL, was signiﬁcantly lower in
NASH, HCV G1, HCV G1 + NAST, and HCV G3.
Hepatocyte apoptosis and hepatic ﬁbrogenesis are increased in NASH
and HCV patients
In NL and NAST patients, no TUNEL-positive cells were identiﬁed
whereas scattered TUNEL-positive cells were observed in NASH
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Fig. 2. Hepatic insulin signaling is impaired in NASH and HCV patients. (A)
Representative Western blotting showing the level and phosphorylation status of
Akt, FoxO1, and AMPK a proteins. (B) Bar graph shows the mean ± SD of hepatic
protein amount in the study groups. Data are the ratio of phospho/total band of
each protein and are presented as percentage relative to NL (100%). *p <0.05,
**p <0.001 vs. NL.
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patients (Fig. 3A, left). Of note apoptotic hepatocytes were more
frequent in all HCV patient groups (Fig. 3A, right).
Hepatic mRNA levels of collagen a1 (I) (COL1A1) were mea-
sured as markers of liver ﬁbrogenesis [22]. When compared with
NL, mRNA levels of COL1A1 were similar in NAST but signiﬁcantly
increased in NASH (2.2-fold), HCV G1 (5.3-fold), HCV G1+NAST
(4.5-fold), and HCV G3 (3.4-fold) (Fig. 3B, left) but no signiﬁcant
differences were observed among the HCV groups when HCV G3
was used as control (Fig. 3B, right).
On the other hand, compared with NL, hepatic mRNA levels
of Mcl-1 and Bcl-2 were signiﬁcantly diminished in NASH (0.56
and 0.60-fold, respectively), HCV G1 (0.97 and 0.98-fold,
respectively), HCV G1+NAST (0.92 and 0.96-fold, respectively),
and HCV G3 (0.93 and 0.97-fold, respectively) but not in NAST
patients (Fig. 4A, left). When the HCV G3 group was used as
control and comparing with HCV G1 and HCV G1+NAST, the
expression levels of these transcripts were similar among the
distinct HCV groups (Fig. 4A, right). As shown in Fig. 4B and
C, the hepatic abundance of Mcl-1 protein was signiﬁcantly
lower in NASH (67%), HCV G1 (56%), HCV G1+NAST (66%),
and HCV G3 (67%) than in NL and NAST patients, whereas
the amount of Bcl-2 protein was similar among the different
patient groups. Moreover, the hepatic content of active caspase
3 was signiﬁcantly higher in NASH (410%), HCV G1 (330%),
HCV G1 + NAST (380%), and HCV G3 (380%) than in NL and
NAST patients.
Hepatic expression of insulin signaling genes correlates with
antiapoptotic and ﬁbrogenic genes in NASH and HCV patients
A positive correlation was found between hepatic mRNA levels
of IRS1 and those of Mcl-1 and Bcl-2 in patients with NASH,
whereas a negative correlation was observed with COL1A1 in
the same patients (Fig. 5). Regarding HCV patients, a positive
correlation was also found between hepatic mRNA levels of
IRS1 and those of Mcl-1 and Bcl-2 in patients with HCV G1,
HCV G1+NAST, and HCV G3, whereas a negative correlation
was observed with COL1A1 in the same patient groups
(Fig. 6). Similar correlations have been found with IRS2 and
p85a.
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HCV core protein induced insulin resistance in cultured human liver
cells
After stimulation with 10 nM insulin for 10 min, the phosphory-
lation of Akt at Ser473 was signiﬁcantly decreased in human hepa-
tocytes transfected with HCV core protein as compared with
control cat-transfected cells (Fig. 7). Moreover, incubation of
HCV-transfected cells with 100 lM stearic acid for 24 h further
reduced insulin-mediated Akt phosphorylation. In addition, we
observed that HCV core overexpression increased the phosphor-
ylation of c-Jun N-terminal kinase (JNK) and IRS1 at Ser312 (2.5-
fold in both cases with respect to control cells). A noteworthy
observation was the ﬁnding that JNK phosphorylation was signif-
icantly enhanced in these cells (6.0-fold higher than controls)
when they were incubated for 24 h with stearic acid before insu-
lin stimulation. Finally, using an identical experimental protocol,
we obtained similar results regarding the effect of HCV NS5A pro-
tein on the phosphorylation levels of Akt and JNK in cultured
human hepatocytes (data not shown).
Discussion
The current study demonstrates that hepatic mRNA and protein
levels of insulin signaling molecules are signiﬁcantly decreased
in NASH and in HCV patients with or without steatosis and
regardless of viral genotype, whereas these parameters are
unchanged in NAST with respect to NL individuals. These obser-
vations indicate that the hepatic insulin signaling cascade is
normal in patients with simple steatosis, favouring the notion
that hepatic fat accumulation precedes disruption of hepatic
insulin signaling at the molecular level. Furthermore, our results
show that the insulin signaling pathway is clearly impaired in
patients with steatohepatitis, reinforcing our assumption that
downregulation of hepatic insulin mediators is a late event in
NAFLD outcome. However, there are contradictory data concern-
ing the relationship between NAFLD and hepatic IR. While clin-
ical studies and animal models indicate that fatty liver may
directly induce hepatic IR [23,24], there is increasing evidence
against this concept as shown in mice overexpressing the DGAT
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gene [25] and in mice with a siRNA-mediated knockdown of the
ECHS1 gene in the liver [26], which develops hepatic steatosis
without IR. Subjects with fatty liver and normal insulin sensitiv-
ity who bore a single nucleotide polymorphism in the DGAT2
[27] and PNPLA3 [28] genes also develop hepatic steatosis with-
out IR. These divergent results are likely related to the variabil-
ity of animal models and NAFLD patients because of
environmental and genetic factors and also can be due to the
different methods used for hepatic IR assessment. In this regard,
only one study evaluating hepatic IR at the gene expression
level in a small cohort of NAFLD patients has been published
so far [29]. These authors found that insulin signaling mediators,
such as pAkt and pFoxO1, were signiﬁcantly decreased in NASH
patients with respect to NL subjects, remaining unchanged or
slightly downregulated in patients with simple steatosis. These
ﬁndings are in agreement with our present results, supporting
the hypothesis that the impairment of insulin signaling in the
liver likely occurs via the effects of oxidative stress and cytokine
release, both common pathogenic features of NASH [4].
On the other hand, although we have observed a trend to
lower HOMA-IR values in HCV G3 patients than in those with
HCV G1, hepatic insulin signaling was impaired at a similar
extent in both groups of HCV patients regardless of the pres-
ence of steatosis, in line with previous reports supporting a
direct role of HCV in the development of IR [11,30]. It is well
known that tyrosine-phosphorylated IRS1 is an upstream medi-
ator of Akt activation [31] whereas serine phosphorylation neg-
atively modulates IRS1-mediated insulin signaling [32].
Moreover, JNK phosphorylates human IRS1 at the Ser312 resi-
due, thereby blocking its tyrosine phosphorylation and, conse-
quently, Akt-mediated insulin signaling [33]. Our in vitro data
show a signiﬁcant increase in JNK and IRS1 Ser312 phosphory-
lation by overexpression of the HCV core protein in human
hepatocytes accompanied with a signiﬁcant decrease in Akt
phosphorylation. These results and others recently reported
[34] suggest that hepatic IR in HCV patients could be due, at
least in part, to the increased phosphorylation of JNK in
HCV-infected hepatocytes that impair the downstream Akt-sig-
naling pathway, identifying JNK as a potential molecular target
of HCV-induced IR.
Although increased hepatocyte apoptosis is now considered as
an important factor contributing to liver disease progression in
NASH and HCV patients [35,36], the elucidation of the underlying
molecular mechanisms is still an active ﬁeld of research. The
present study conﬁrms by TUNEL assay the occurrence of
increased hepatocyte apoptosis in NASH and HCV patients, and
extends these observations by demonstrating a signiﬁcant
decrease of hepatic mRNA levels of Bcl-2 and Mcl-1, both key
antiapoptotic mediators, as well as a signiﬁcant increase of active
caspase 3, the ﬁnal executor of apoptosis, in NASH and HCV
patients with respect to NAST and NL subjects. In addition, we
observed a positive correlation between the hepatic mRNA levels
of IRS1, IRS2, p85a, and antiapoptotic mediators, indicating that
impairment of the hepatic insulin signaling pathway is closely
associated with enhanced hepatocyte apoptosis in NASH and
HCV patients. This is a novel ﬁnding in line with the notion that
insulin exerts antiapoptotic functions in many cell types [37]. In
particular, we have reported that IRS2 plays an essential role in
mediating the antiapoptotic action of insulin in mouse hepato-
cytes [38]. Thus, it is conceivable that the low hepatic levels of
IRS1/2 proteins found in NASH and HCV patients might explain,
at least in part, the enhanced hepatocyte apoptosis observed in
these patients.
A number of clinical studies suggest that IR is associated with
ﬁbrosis progression in NAFLD and HCV patients [9,11]. However,
since ﬁbrogenesis is a complex and dynamic process [39], histo-
logical analysis of ﬁbrosis stage is unsuitable to evaluate active
ﬁbrogenesis. To our knowledge, the current study is the ﬁrst work
measuring insulin signaling targets along with type I collagen
gene levels in liver biopsies from NAFLD and HCV patients. Our
results show a negative correlation between hepatic mRNA levels
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of IRS1, IRS2, and p85a, and type I collagen showing that disrup-
tion of hepatic insulin signaling is associated with increased liver
ﬁbrogenesis in both conditions. Plausible mechanisms exist to
explain a potential role of hepatic IR in ﬁbrogenesis. Enhanced
apoptosis associated with hepatic IR, as we have shown herein,
may lead to activation of hepatic stellate cells (HSC) either by
the engulfment of apoptotic cells [40] or by a direct effect of
Kupffer cells following phagocytosis of apoptotic bodies [41]. In
addition, IR-related hyperinsulinemia can stimulate HSC to pro-
liferate and secrete type I collagen [42]. Our present data along
with others showing that amelioration of IR improved hepatic
ﬁbrosis in NASH and HCV patients suggest that hepatic IR may
contribute to ﬁbrogenesis in both entities.
In conclusion, this study demonstrates that hepatic insulin
signaling is markedly impaired in NASH and HCV patients, and
downregulation of hepatic insulin mediators is associated with
enhanced hepatocyte apoptosis and ﬁbrogenesis in both condi-
tions. Moreover, we show that increased phosphorylation of
JNK is involved in HCV-induced IR. Our data provide a rationale
to address the effect of interventions aimed to improve hepatic
insulin sensitivity in attenuating liver injury and ﬁbrosis progres-
sion in these chronic liver diseases.
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